Wendy Mcdermott
Oficial de Recursos Humanos en LEXICON PHARMACEUTICALS, INC. .
Fortuna: 81 149 $ al 30/04/2024
Cargos activos de Wendy Mcdermott
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Oficial de Recursos Humanos | 01/01/2022 | - |
Historial de carrera de Wendy Mcdermott
Antiguos cargos conocidos de Wendy Mcdermott.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Sanofi Corp. | Oficial de Recursos Humanos | 01/01/2017 | 01/01/2019 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Oficial de Recursos Humanos | 01/01/2019 | - |
Formación de Wendy Mcdermott.
| State University of New York College at Plattsburgh | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Bolsa de valores
- Insiders
- Wendy Mcdermott
- Experiencia
